Prescription Required
Glyxambi 10mg/5mg Tablet is a combination medicine used to manage type 2 diabetes mellitus effectively. It contains Empagliflozin (10mg) and Linagliptin (5mg), which work together to control blood sugar levels and improve glycemic control. Empagliflozin helps eliminate excess glucose through urine, while Linagliptin enhances insulin secretion and reduces sugar production in the liver.
This combination is particularly beneficial for patients requiring dual therapy for better blood sugar management. It may also provide cardiovascular benefits and reduce the risk of diabetes-related complications. Glyxambi Tablet is not recommended for type 1 diabetes or diabetic ketoacidosis. Always use this medication under medical supervision and combine it with a balanced diet and regular exercise for the best results.
Avoid excessive alcohol consumption as it may increase the risk of low blood sugar (hypoglycemia) and dehydration.
Glyxambi 10mg/5mg Tablet is not recommended during pregnancy unless prescribed by a doctor. Discuss the risks and benefits before use.
Not advised for breastfeeding mothers as it may pass into breast milk. Consult a healthcare provider.
May cause dizziness or low blood sugar, affecting concentration. Avoid driving if you experience such effects.
Use with caution in patients with kidney impairment, as Empagliflozin can affect kidney function. Regular monitoring is necessary.
Safe for most liver patients but should be used with caution in severe liver disease. Consult your doctor for dosage adjustments.
Glyxambi 10mg/5mg Tablet is a dual-action anti-diabetic medicine containing Empagliflozin and Linagliptin. Empagliflozin belongs to the SGLT2 inhibitors class, which prevents glucose reabsorption in the kidneys, promoting its excretion through urine. This mechanism helps lower blood sugar levels while also aiding in weight loss and reducing blood pressure. Linagliptin, a DPP-4 inhibitor, increases insulin secretion and decreases glucose production in the liver, enhancing overall glycemic control. Together, these components provide better blood sugar management than single-drug therapies. Additionally, Empagliflozin has been shown to offer heart and kidney protection, making Glyxambi a preferred choice for diabetic patients with cardiovascular risks.
Type 2 diabetes occurs when the body cannot effectively use insulin, leading to high blood sugar levels. It is often linked to obesity, sedentary lifestyle, and genetics. Managing diabetes involves medication, lifestyle changes, and regular monitoring to prevent complications such as heart disease, kidney damage, and nerve issues.
Content Updated on
Wednesday, 5 Feburary, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA